Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2020-01-22 Interim / Quarterly Rep…
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Appendix 4C - Quarterly 5 pages 187.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed consolidated cash flow statements for the current quarter and year to date, including operating, investing, and financing activities. It also includes estimated cash outflows for the next quarter and a compliance statement signed by the company secretary. The document is approximately 9,000 characters long, which is substantial and contains actual financial data and analysis for a quarterly period. The presence of detailed financial statements and the quarterly period reference aligns with the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or a certification, but a substantive financial report. Therefore, the correct classification is IR (Interim / Quarterly Report). Q4 2019
2020-01-22 English
Appointment of New Director 1 page 59.7KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated January 13, 2020, regarding the appointment of a new Non-Executive Director, Matthew Patrick McNamara, to the board of Avecho Biotechnology Limited. The content focuses solely on the change in the company's board of directors and provides background information on the new director. There is no financial data, report publication, or other regulatory information present. The document is short (2846 characters) and clearly an announcement of a management change. Therefore, it fits the category of Board/Management Information (MANG).
2020-01-12 English
Initial Director's Interest Notice 2 pages 131.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities and contracts, with no securities held. This is a report of personal share transactions or interests by a company director. The document length is short and focused solely on director's interests, matching the definition of Director's Dealing filings. Therefore, the appropriate classification is DIRS (Director's Dealing).
2020-01-12 English
Injectable Portfolio Update - Products Differentiated by TPM 26 pages 1.2MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement dated December 4, 2019, titled 'Injectable Portfolio Update: Products Differentiated by TPM®'. It provides detailed information about the company's injectable product portfolio, technology, market potential, and product benefits. The content is a corporate update aimed at investors and stakeholders, focusing on product development and market strategy rather than financial results or regulatory filings. It is not a full financial report, audit report, or earnings release. It is also not a call transcript, board management change, or legal proceeding. The document is a detailed investor update presentation about the company's product portfolio and technology, which fits the definition of an Investor Presentation (IP). The length (15,000 characters) and detailed content support this classification rather than a brief announcement or report publication announcement.
2019-12-03 English
Change in substantial holding 4 pages 2.0MB
Regulatory Filings
2019-10-21 English
Terumo return rights to TPM/Propofol Injectable 2 pages 67.5KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Avecho Biotechnology Limited on the ASX platform, discussing the termination of a development partnership with Terumo Corporation regarding a specific drug formulation. It provides detailed information about the product, the reasons for discontinuation, and forward-looking statements about the company's business and risks. There are no financial statements, quarterly or annual results, or regulatory certifications. The content is an update on a business development and partnership status rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is a general regulatory announcement about business operations and product development status. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2019-10-16 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.